GLENMARK PHARMACEUTICALS
|
GLENMARK PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 48.26 | 37.11 | -53.21 | 10.53 | 33.37 |
| CEPS(Rs) | 68.58 | 54.33 | -44.26 | 17.00 | 52.46 |
| DPS(Rs) | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 |
| Book NAV/Share(Rs) | 371.30 | 313.28 | 277.46 | 335.13 | 321.45 |
| Tax Rate(%) | 31.38 | 25.16 | 5,116.71 | 137.34 | 31.06 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 13.21 | 8.19 | 4.31 | 5.79 | 8.35 |
| EBIT Margin(%) | 6.34 | 5.60 | 1.99 | 2.09 | 6.26 |
| Pre Tax Margin(%) | 5.73 | 4.87 | 0.13 | 0.85 | 5.18 |
| PAT Margin (%) | 3.93 | 3.65 | -6.61 | -0.32 | 3.57 |
| Cash Profit Margin (%) | 5.59 | 5.34 | -4.51 | 1.70 | 5.32 |
| Performance Ratios | |||||
| ROA(%) | 8.11 | 7.42 | -11.86 | -0.54 | 6.74 |
| ROE(%) | 14.10 | 12.56 | -21.18 | -0.97 | 12.33 |
| ROCE(%) | 20.35 | 16.16 | 4.88 | 4.43 | 14.19 |
| Asset Turnover(x) | 2.06 | 2.03 | 1.79 | 1.71 | 1.89 |
| Sales/Fixed Asset(x) | 3.09 | 2.87 | 2.77 | 2.74 | 2.94 |
| Working Capital/Sales(x) | 7.03 | 8.62 | 17.22 | 7.28 | 7.74 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.32 | 0.35 | 0.36 | 0.36 | 0.34 |
| Receivable days | 43.78 | 33.06 | 36.38 | 43.76 | 37.24 |
| Inventory Days | 34.05 | 35.23 | 32.19 | 31.52 | 31.35 |
| Payable days | 264.58 | 237.83 | 190.23 | 186.18 | 191.57 |
| Valuation Parameters | |||||
| PER(x) | 44.21 | 41.50 | - | 44.14 | 13.25 |
| PCE(x) | 31.11 | 28.35 | -21.63 | 27.36 | 8.43 |
| Price/Book(x) | 5.75 | 4.92 | 3.45 | 1.39 | 1.38 |
| Yield(%) | 0.12 | 0.16 | 0.26 | 0.54 | 0.57 |
| EV/Net Sales(x) | 3.48 | 3.30 | 2.23 | 1.41 | 1.20 |
| EV/Core EBITDA(x) | 11.73 | 17.83 | 12.95 | 8.48 | 5.93 |
| EV/EBIT(x) | 26.91 | 27.36 | 47.70 | 27.69 | 8.47 |
| EV/CE(x) | 5.61 | 3.98 | 2.98 | 1.18 | 1.16 |
| M Cap / Sales | 3.54 | 3.26 | 2.29 | 1.13 | 1.01 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 27.48 | 12.77 | 1.98 | -5.86 | 12.44 |
| Core EBITDA Growth(%) | 104.17 | 21.12 | 5.79 | -22.64 | 16.51 |
| EBIT Growth(%) | 36.56 | 190.75 | -6.18 | -66.14 | 0.22 |
| PAT Growth(%) | 30.06 | 157.19 | -1,944.25 | -109.01 | 2.43 |
| EPS Growth(%) | 30.06 | 169.73 | -605.16 | -68.44 | -2.92 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | 0.25 | 0.13 | 0.46 | 0.40 |
| Current Ratio(x) | 1.77 | 1.56 | 1.28 | 1.85 | 1.77 |
| Quick Ratio(x) | 1.23 | 1.05 | 0.84 | 1.33 | 1.23 |
| Interest Cover(x) | 10.51 | 7.76 | 1.07 | 1.69 | 5.83 |
| Total Debt/Mcap(x) | - | 0.05 | 0.04 | 0.33 | 0.29 |
Compare Financial Ratios of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹66,034.8 Cr | 1.9% | 2.3% | 11.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹461,848.0 Cr | -1.4% | -1.3% | 21.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹225,648.0 Cr | 2.7% | 16.1% | 38.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹184,109.0 Cr | -1.5% | -3.3% | 35.6% | Stock Analytics | |
| CIPLA | ₹117,139.0 Cr | -0.7% | 1.4% | -2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,328.0 Cr | 3.9% | -1.8% | 0.4% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 1.9% |
2.3% |
11.2% |
| SENSEX | -0.6% |
1.1% |
-3.2% |
You may also like the below Video Courses
